NEW ORLEANS – September 1, 2017 – Touro Infirmary is proud to introduce the UroNav fusion biopsy system, a cutting-edge option for diagnosing prostate cancer for many patients with elevated and/or rising PSA levels, to our hospital. The UroNav combines pre-biopsy MR images with ultrasound technology to better detect suspicious lesions, delineation of the prostate and clear visualization of the biopsy needle.
The MRI and ultrasound images use electromagnetic tracking for a more targeted biopsy. A tiny, navigation sensor is attached to an ultrasound probe, which generates a localized electromagnetic field to determine the location. The UroNav also provides better post-biopsy review through visualization and recording in multiple 2D and 3D views.
“We are committed to providing the highest quality of care to our patients, and the UroNav is poised to become a new standard in prostate care,” says Touro Urologist Richard M. Vanlangendonck Jr., M.D. “The UroNav fusion biopsy system allows surgeons to achieve more accurate biopsies in the prostate in return providing more accurate diagnoses.”
Other than skin cancer, prostate cancer is the most common form of cancer in American men and the second-leading cause of cancer death in this population. One in six men will be diagnosed with prostate cancer during his lifetime.
Historically, urologists have had a difficult time distinguishing between moderate and aggressive lesions in the prostate. UroNav is the next generation of prostate cancer detection because it accurately identifies and tests areas for more precise diagnosis.